Highest-materiality recent filing
SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt
Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
Scienture shareholders reject 20x authorized share increase; approve reverse split and equity plan
Proposal to boost authorized common shares from 100M to 2B and preferred from 10M to 200M was rejected (5.3M for, 5.5M against).
Scienture increases at-the-market equity facility to $150M via Maxim Group
Maximum aggregate offering price under ATM agreement raised to $150 million; entire amount remains available as of Nov 7, 2025.
Scienture receives Nasdaq delisting notice for bid price below $1.00
Notice received Oct 14, 2025 for non-compliance with Nasdaq Listing Rule 5450(a)(1).
Scienture refinances $2.7M NVK loan with $3.9M Streeterville note, issues 250K shares
Entered $3,911,111 senior secured note (net $3.5M) with Streeterville Capital; 9% interest, 7-month term.
Scienture Holdings converts $559K debentures to equity at $2.4861/share, terminates Arena debt
Conversion price of 10% OID secured debentures amended to $2.4861 per share.
Scienture Holdings enters $9.2M ATM equity distribution agreement with Maxim Group
Total gross sales price up to $9.2M under shelf registration (Form S-3).
Scienture raises ~$3.9M via registered direct offering of 3.225M shares at $1.20/share
Offering of 3,225,000 shares at $1.20/share for gross proceeds of ~$3.9M; closed August 15, 2025.
Scienture raises up to $3M in bridge funding; secures $1.2M initially
Board approved capital raise of up to $3M; Company sold 754,716 shares at $1.59 per share.
Scienture Holdings CEO and President resign; Nasdaq bid-price deficiency received
CEO Suren Ajjarapu and Chairman resigned May 16; President Prashant Patel resigned May 20, both no disputes.
Scienture divests IPS and Bonum to Tollo for $5M note; focuses on Specialty Pharma
Total consideration is $5M in a promissory note bearing interest at prime rate, maturing June 30, 2030.
Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025
FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.
Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva
Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.
Scienture receives Nasdaq delisting notice for missing 2024 annual meeting; corrects prior 8-K
Received Nasdaq notice on Jan 3, 2025 for non-compliance with Listing Rule 5620(a) due to no 2024 annual meeting.
Scienture secures $3M first tranche of convertible debentures and $50M ELOC
First closing on Nov 25, 2024: $3,333,333 principal of 10% OID secured convertible debentures issued for $3,000,000.
TRxADE HEALTH completes merger with Scienture; issues Series X preferred convertible to common
Closed merger with Scienture Inc. on July 25; Scienture holders get 291,555 common shares (19.99% of pre-deal float) and 6,826,713 Series X non-voting convertible preferred shares.
TRxADE Health declares special $1.50/share dividend from asset sale proceeds
Special cash dividend of $1.50 per share of common stock declared by board.
Received Nasdaq notice on May 23, 2024 for failing to timely file Q1 10-Q; must submit compliance plan by July 22, 2024.
TRxADE Health still unable to file Q1 10-Q, faces potential Nasdaq compliance issue
Filed Form 12b-25 on May 15, but still unable to file Q1 10-Q for period ended March 31, 2024.
TRxADE Health declares $8 special dividend from asset sale proceeds
Special cash dividend of $8.00 per share declared; payable March 22, 2024 to holders of record March 18, 2024.
TRxADE Health sells Trxade marketplace assets to Micro Merchant Systems for $22.5M
Base purchase price $22.5M cash at closing; additional $7.5M earnout if MMS collects ≥$1.6M from third parties within 4 months.
TRxADE Health files late Q3 2023 10-Q, says regains Nasdaq compliance
Filed Form 10-Q for period ended Sep 30, 2023, which was overdue since Nov 2023.
Superlatus failed to meet post-closing condition to acquire Prestige Farms, leading to material breach.
TRxADE HEALTH receives Nasdaq delinquency notice for late 10-Q filing
Received Nasdaq notice on Nov 21, 2023 for non-compliance with Listing Rule 5250(c)(1).
TRxADE HEALTH delays Q3 10-Q filing; expects Nasdaq non-compliance notice
Company will not file Q3 2023 10-Q within the five-day grace period under Rule 12b-25.
Superlatus appoints Rainforest as exclusive distributor in North Atlantic, Northeast, Midwest, Mid-Atlantic regions for CPG brands like Coolhaus and Spero.
TRxADE closes Superlatus acquisition, regains Nasdaq compliance
Acquired Superlatus; shareholders received 136,441 common shares (19.99% stake) and 306,855 Series B Preferred (100:1 conversion).
TRxADE Health amends merger with Superlatus; adds share rights for existing holders
Superlatus shareholders get 30,821,941 shares at $7.30: 136,441 common (19.99% post-merger) and 306,855 Series B convertible preferred (100:1).
TRxADE Health to acquire Superlatus, shifting to food & snack industry; new shares to be issued.
Superlatus shareholders receive 173,463 MEDS shares (136,436 common, 37,027 Series B preferred convertible at 100:1).
TRxADE Health receives Nasdaq delisting notice for insufficient public shares
Nasdaq notified TRxADE on June 23, 2023, that it had ~310,057 publicly held shares, below the 500,000 minimum.
the Company appointed Dr. Narasimhan Mani (age 51) to serve as the Company’s Interim Chief Financial Officer ("Interim CFO") effective as of May 26, 2026.
On May 26, 2026, Eric Sherb, the Chief Financial Officer ("CFO") of Scienture Holdings, Inc. (the "Company"), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of directors.
On May 16, 2025, as part of a planned leadership succession, Suren Ajjarapu advised the Company that he was resigning from his position as the Company’s Chief Executive Officer and Chairman of the Board effective immediately.
the Company’s board of directors appointed Dr. Narasimhan Mani, age 50, and Dr. Shankar Hariharan, age 68, to serve as co-Chief Executive Officers of the Company effective as of May 20, 2025.
As part of the planned leadership transition, Prashant Patel also advised the Company that he was resigning from his position as the Company’s President and Chief Operating Officer, effective as of May 20, 2025.
The board of directors also appointed Dr. Mani to serve as a director on the Company’s board of directors to fill the vacancy created as a result of Mr. Ajjarapu’s resignation and appointed Dr. Hariharan to the position of Executive Chairman of the Company’s board of directors, each effective as of May 20, 2025.
Mr. Patel notified the Company’s Board of Directors of his intention to resign his position as Interim Principal Financial/Accounting Officer effective as of the Effective Date.
On March 13, 2025, the Board of Directors of Scienture Holdings, Inc. (the “Company”) appointed Eric Sherb to serve as the Company’s Chief Financial Officer effective as of March 13, 2025
On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.
On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
Max materiality 0.90 · Median 0.65 · Most common event other_material